Biohaven (BHVN) Liabilities and Shareholders Equity (2021 - 2026)

Biohaven (BHVN) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $466.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 1.63% year-over-year to $466.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (down 13.37% YoY), and the FY2025 full-year result was $451.4 million, down 26.61% from the prior year.
• Liabilities and Shareholders Equity improved to $466.4 million in Q1 2026, from $451.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $661.8 million in Q4 2022 to a low of $135.6 million in Q3 2022.
• A 5-year average of $485.5 million and a median of $506.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 365.84% in 2022 and sank 32.33% in 2024, its largest moves.
• Tracing BHVN's Liabilities and Shareholders Equity over 5 years: stood at $661.8 million in 2022, then slipped by 22.45% to $513.2 million in 2023, then rose by 19.85% to $615.1 million in 2024, then declined by 26.61% to $451.4 million in 2025, then grew by 3.31% to $466.4 million in 2026.
• Business Quant data shows BHVN's Liabilities and Shareholders Equity at $466.4 million in Q1 2026, $451.4 million in Q4 2025, and $409.1 million in Q3 2025.